Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
10:04am, Friday, 25'th Jul 2025
Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy, Elevidys.
NEW YORK , July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
08:34am, Friday, 25'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the Committee for Medicinal Products for Huma
Goldman Sachs' Salveen Richter on Sarepta's ongoing troubles, opportunities in biotech
08:10am, Friday, 25'th Jul 2025
Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Squawk Box' to discuss the troubles facing Sarepta and its muscular dystrophy drug Elevidys, state of the biotech sector, what to expect on
EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy
07:13am, Friday, 25'th Jul 2025
Europe's medicines regulator did not recommend the approval of Sarepta Therapeutics' gene therapy Elevidys for a type of rare muscular dystrophy, the health agency said on Friday.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
Investors in Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT
04:00pm, Thursday, 24'th Jul 2025
NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.
02:55pm, Thursday, 24'th Jul 2025
Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety profile of Elevidys.
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders
08:45am, Thursday, 24'th Jul 2025
NEW YORK , July 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during t
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Is This Stock a Buy After Soaring by 20% in 1 Day?
07:40am, Thursday, 24'th Jul 2025
It's been a rough year for Sarepta Therapeutics (SRPT -2.24%), a small-cap biotech that develops medicines for rare diseases. The company's shares are down by 88% year to date due to safety issues wit
SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) collapse again – this time, shares closed down
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
04:08pm, Wednesday, 23'rd Jul 2025
NEW YORK , July 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 an
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
11:53am, Wednesday, 23'rd Jul 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options If you su
Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks
08:05am, Wednesday, 23'rd Jul 2025
Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as part of their licensing agreement, despite recent setbacks at the Cambridge,
